Grace Therapeutics, Inc. Logo

Grace Therapeutics, Inc.

Develops improved drugs for rare neurological diseases using novel drug delivery technologies.

GRCE | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
103 CARNEGIE CENTER, 8540 PRINCETON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing drug candidates for rare and orphan diseases, with a particular emphasis on neurological conditions. The company utilizes novel drug delivery technologies to improve the performance of currently marketed drugs. Its lead clinical asset, GTx-104, is an intravenous (IV) formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH), an acute brain injury. Currently in a pivotal Phase 3 trial, GTx-104 is designed to overcome the significant limitations of the existing oral standard of care. The asset has been granted Orphan Drug Designation by the U.S. FDA, and the company is supported by a strong, multi-layered intellectual property portfolio.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Grace Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Grace Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Grace Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America CERO
CervoMed Inc. Logo
Developing CNS therapeutics for neurodegenerative diseases like dementia with Lewy bodies.
United States of America CRVO
Cessatech A/S Logo
Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.
Denmark CESSA
CG Invites Co., Ltd. Logo
Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.
South Korea 083790
CG Oncology, Inc. Logo
Developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.
United States of America CGON
CHA Vaccine Research Institute Logo
Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.
South Korea 261780
Manufactures veterinary medicines and feed additives for livestock, aquatic animals, and pets.
South Korea 052670
Chemical Works of Gedeon Richter Plc Logo
Develops and manufactures drugs for women's health, CNS, and cardiovascular diseases.
Hungary RICHT
Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America CPHI

Talk to a Data Expert

Have a question? We'll get back to you promptly.